Perioperative pembrolizumab and the changing paradigm of adjuvant therapy in head and neck squamous cell carcinoma: the case of T1-2, pN1. Tirelli G, Boscolo-Rizzo P. Oral Oncol 2025;171:107770.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tirelli G, Boscolo-Rizzo P. Perioperative pembrolizumab and the changing paradigm of adjuvant therapy in head and neck squamous cell carcinoma: the case of T1-2, pN1. Oral Oncol 2025;171:107770.
PMID: 41197427